Efficacy of elobixibat for elderly patients with chronic constipation in a clinic.

Yuji Sakai, Toshio Tsuyuguchi, Junichiro Kumagai, Hiroshi Ohyama, Takashi Kaiho, Masayuki Ohtsuka, Naoya Kato
{"title":"Efficacy of elobixibat for elderly patients with chronic constipation in a clinic.","authors":"Yuji Sakai, Toshio Tsuyuguchi, Junichiro Kumagai, Hiroshi Ohyama, Takashi Kaiho, Masayuki Ohtsuka, Naoya Kato","doi":"10.4292/wjgpt.v16.i2.105801","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Elobixibat reportedly improves bowel movements in patients with chronic constipation. However, its effect on bowel movements in elderly patients with chronic constipation in clinical settings has not been examined.</p><p><strong>Aim: </strong>To examine bowel movement frequency and stool form before and after elobixibat administration in elderly patients with chronic constipation at our clinic.</p><p><strong>Methods: </strong>A total of 10 mg elobixibat was administered to 35 (< 65 years old) patients and 45 (≥ 65 years old) patients with chronic constipation. The frequency of bowel movements and stool forms, assessed using the Bristol Stool Form Scale (BSFS), were compared between the two groups 1 week before and after elobixibat administration.</p><p><strong>Results: </strong>In patients aged < 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.167 ± 0.732 and 2.286 ± 0.742, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 2.389 ± 0.502 and 3.995 ± 0.566, respectively, showing a significant improvement in bowel movement status. In patients aged ≥ 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.003 ± 0.733 and 2.217 ± 0.758, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 4.402 ± 1.346 and 3.800 ± 0.704, respectively, indicating an improvement in bowel movement status (<i>P</i> < 0.001). No significant differences were observed in the frequency and improvement status of bowel movements or BSFS scores between patients with chronic constipation aged ≥ 65 years and < 65 years. Adverse events due to the administration of elobixibat occurred in 16 cases (20%). No significant differences were found in the incidence of adverse events between patients with chronic constipation aged < 65 years (8 cases, 22.9%) and those aged ≥ 65 years (8 cases, 17.8%).</p><p><strong>Conclusion: </strong>Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients.</p>","PeriodicalId":60311,"journal":{"name":"世界胃肠药理与治疗学杂志:英文版(电子版)","volume":"16 2","pages":"105801"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188903/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界胃肠药理与治疗学杂志:英文版(电子版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4292/wjgpt.v16.i2.105801","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Elobixibat reportedly improves bowel movements in patients with chronic constipation. However, its effect on bowel movements in elderly patients with chronic constipation in clinical settings has not been examined.

Aim: To examine bowel movement frequency and stool form before and after elobixibat administration in elderly patients with chronic constipation at our clinic.

Methods: A total of 10 mg elobixibat was administered to 35 (< 65 years old) patients and 45 (≥ 65 years old) patients with chronic constipation. The frequency of bowel movements and stool forms, assessed using the Bristol Stool Form Scale (BSFS), were compared between the two groups 1 week before and after elobixibat administration.

Results: In patients aged < 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.167 ± 0.732 and 2.286 ± 0.742, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 2.389 ± 0.502 and 3.995 ± 0.566, respectively, showing a significant improvement in bowel movement status. In patients aged ≥ 65 years with chronic constipation, the pre-elobixibat frequency of bowel movements and BSFS scores were 2.003 ± 0.733 and 2.217 ± 0.758, respectively. After elobixibat administration, the frequency of bowel movements and BSFS scores improved to 4.402 ± 1.346 and 3.800 ± 0.704, respectively, indicating an improvement in bowel movement status (P < 0.001). No significant differences were observed in the frequency and improvement status of bowel movements or BSFS scores between patients with chronic constipation aged ≥ 65 years and < 65 years. Adverse events due to the administration of elobixibat occurred in 16 cases (20%). No significant differences were found in the incidence of adverse events between patients with chronic constipation aged < 65 years (8 cases, 22.9%) and those aged ≥ 65 years (8 cases, 17.8%).

Conclusion: Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients.

依洛比昔巴特治疗老年慢性便秘临床疗效观察。
背景:据报道,依洛比西巴特可以改善慢性便秘患者的排便。然而,其对老年慢性便秘患者排便的影响尚未在临床研究中得到证实。目的:观察我院老年慢性便秘患者依洛比昔巴服用前后的排便频率和大便形态。方法:35例(< 65岁)慢性便秘患者和45例(≥65岁)慢性便秘患者共服用10 mg依洛比昔巴。使用布里斯托大便形式量表(BSFS)评估排便频率和大便形式,比较两组在给予埃洛比昔巴前后1周的排便频率。结果:年龄< 65岁的慢性便秘患者,使用依比昔巴前排便频率和BSFS评分分别为2.167±0.732和2.286±0.742。给药后,排便频率和BSFS评分分别改善至2.389±0.502分和3.995±0.566分,排便状况明显改善。年龄≥65岁的慢性便秘患者,使用依比昔巴前排便频率和BSFS评分分别为2.003±0.733和2.217±0.758。给药后,排便频率和BSFS评分分别改善至4.402±1.346和3.800±0.704,表明排便状况改善(P < 0.001)。≥65岁和< 65岁慢性便秘患者的排便频率和改善状况或BSFS评分无显著差异。16例(20%)患者因服用埃洛比西他而发生不良事件。年龄< 65岁慢性便秘患者(8例,22.9%)与年龄≥65岁慢性便秘患者(8例,17.8%)不良事件发生率无显著差异。结论:依洛比西他能有效改善慢性便秘患者的排便状况。< 65岁和≥65岁慢性便秘患者的排便状况改善及不良事件发生率无显著差异,提示该药可安全用于老年患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
300
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信